Pasteurella / Mannheimia

Pasteurella and Mannheimia vaccines provide critical protection against pneumonic pasteurellosis, one of the most economically significant respiratory diseases affecting sheep and goats worldwide. These vaccines target Mannheimia haemolytica (formerly classified as Pasteurella haemolytica) and related bacterial species that cause severe, often fatal pneumonia in small ruminants, particularly during periods of stress, transportation, or management changes. The respiratory disease complex caused by these organisms costs the sheep and goat industries millions of dollars annually through mortality losses, treatment costs, reduced performance, and chronic respiratory damage in surviving animals.

The vaccine formulations consist of killed bacterial cells combined with leukotoxoid components that stimulate immunity against both the bacterial organisms and their damaging toxins. Mannheimia haemolytica produces a potent leukotoxin that destroys white blood cells and causes the severe lung damage characteristic of pneumonic pasteurellosis. Vaccines containing leukotoxoid antigens stimulate antibodies that neutralize this toxin, providing crucial protection against disease pathogenesis beyond simple antibacterial immunity.

Multiple commercial products are available for sheep, with varying formulations and label claims. Products specifically labeled for sheep include toxoid preparations designed for small ruminant immune systems. Some cattle respiratory vaccines are used extra-label in goats due to limited product availability specifically licensed for caprine species. Veterinary guidance should inform product selection for goat vaccination programs to ensure appropriate formulation choice and dosing protocols.

The biological rationale for Pasteurella/Mannheimia vaccination reflects the multifactorial nature of respiratory disease in small ruminants. While these bacteria are often present as normal respiratory flora, various stressors including transportation, weaning, weather changes, nutritional deficiency, and concurrent infections can precipitate disease in susceptible animals. Vaccination builds baseline immunity that helps animals resist disease development when stressed, reducing the respiratory disease burden across production systems where stress events are unavoidable.

The primary indication for Pasteurella/Mannheimia vaccination is the prevention of pneumonic pasteurellosis in sheep and goat populations facing elevated disease risk due to management events, environmental conditions, or known disease history. Vaccination is particularly valuable before anticipated stress events such as weaning, transportation, commingling with animals from other sources, or movement to feedlot situations where disease pressure intensifies. Building immunity before stress exposure allows animals to better resist the disease challenges that stress precipitates.

Lamb and kid vaccination represents a critical application, as young animals are particularly vulnerable to pneumonic pasteurellosis during the transition from maternal immunity protection to their own active immunity. Vaccination timing must balance the desire for early protection against potential interference from maternal antibodies that may reduce vaccine efficacy in very young animals. Many programs vaccinate at weaning or shortly before, allowing time for immune response development before the stress of separation and dietary change.

Feedlot and finishing operations benefit substantially from respiratory disease vaccination programs that reduce mortality, treatment costs, and performance losses associated with pneumonia outbreaks. Animals entering feedlot situations face compounding stressors including transportation, dietary changes, commingling with diverse source populations, and environmental challenges that create ideal conditions for disease emergence. Vaccination upon arrival or preferably before shipping provides baseline protection during this critical high-risk period.

Breeding flock and herd programs incorporate Pasteurella/Mannheimia vaccination to protect valuable breeding stock from respiratory disease that could impact reproductive performance and longevity. Pregnant animals experiencing respiratory disease may suffer pregnancy losses, reduced colostrum quality, or compromised lamb and kid vitality. Vaccinating breeding females before breeding or during early pregnancy ensures immunity during the production cycle while avoiding vaccination during late gestation.

Show and exhibition animals warrant respiratory vaccination consideration given the disease exposure risks associated with commingling at events. Animals traveling to shows face transportation stress, exposure to animals from diverse health backgrounds, and environmental changes that elevate disease susceptibility. Visible respiratory disease or poor condition from recent illness negatively impacts competitive success and sale values, making prevention particularly important for valuable show stock.

Pasteurella/Mannheimia vaccine administration typically follows either subcutaneous or intramuscular routes depending on product labeling and intended administration site. Subcutaneous administration is generally preferred for sheep to minimize injection site damage to valuable muscle tissue, while some products may specify intramuscular administration. Regardless of route, proper injection technique ensures complete dose delivery and reduces complication risks including injection site reactions and abscesses.

Standard dosing for most commercial products is 2 mL per animal regardless of body weight, though specific products may specify different volumes. Some products designed for young lambs may use reduced doses of 1 mL. Label directions for the specific product selected should always guide dosing decisions, as formulation differences affect appropriate dose volumes. Using doses smaller than labeled recommendations may result in inadequate immune stimulation and protection failure.

Primary vaccination in previously unvaccinated animals requires two doses administered three to four weeks apart to establish protective immunity. The initial dose primes the immune system, while the booster dose stimulates the amplified secondary response that provides durable protection. Skipping the booster dose in primary vaccination programs results in incomplete immunity and significantly reduced protection, representing a common but costly shortcut that undermines program success.

Booster vaccination should be administered annually in adult animals to maintain immunity levels adequate for protection. In high-risk situations or populations with known disease history, more frequent boosters every six months may be warranted. Timing of annual boosters should consider anticipated stress events and disease risk periods, with vaccination scheduled three to four weeks before expected high-risk periods to allow immune response development.

Newly purchased animals should receive vaccination regardless of reported previous vaccination history from source operations. Uncertainty about prior vaccine products, administration quality, and timing justifies treating all incoming animals as unvaccinated for program planning purposes. Quarantine periods should include completion of the primary vaccination series before new animals mix with resident flocks where respiratory disease prevention is prioritized.

Withdrawal time requirements for Pasteurella/Mannheimia vaccines are generally minimal, with most killed bacterial products having 21-day meat withdrawal periods or less. However, specific withdrawal times vary by product and should be verified on product labeling before use in animals approaching slaughter. Milk withdrawal is typically not required for most formulations, but label verification is essential for dairy operations.

Injection site reactions represent the most commonly observed adverse effects following Pasteurella/Mannheimia vaccination, manifesting as localized swelling, firmness, or pain at the administration site. These reactions typically appear within 24 to 48 hours post-vaccination and may persist for several days to weeks depending on individual animal response and the specific adjuvant system used in the vaccine formulation. Most injection site reactions resolve spontaneously without intervention and do not significantly impact animal health or productivity.

Transient systemic reactions including fever, depression, and reduced appetite may occur within the first 24 to 72 hours following vaccination as part of the normal immune activation process. These general signs typically resolve without treatment as the immune response matures. Animals showing prolonged or severe systemic reactions should receive veterinary evaluation to rule out concurrent illness or hypersensitivity responses requiring intervention.

Hypersensitivity reactions ranging from localized urticaria to systemic anaphylaxis occur rarely but represent potentially serious adverse events requiring immediate attention. Animals with previous vaccine exposure face slightly elevated risk of allergic reactions compared to those receiving primary vaccination. Signs of anaphylaxis including facial swelling, respiratory distress, salivation, and collapse require emergency treatment with epinephrine and supportive care. Maintaining epinephrine availability during vaccination sessions enables rapid response to anaphylactic events.

Abscess formation at injection sites may occur, particularly if injection technique allows bacterial contamination of the vaccine depot or if tissue damage from improper needle placement creates conditions favorable for infection. Abscesses may require drainage and topical or systemic antibiotic therapy to resolve. Careful attention to injection site preparation, needle cleanliness, and proper technique minimizes abscess risk. Using single-use needles for each animal rather than reusing needles across multiple animals further reduces contamination risk.

Rare reports of post-vaccination respiratory disease have been documented, though causation is difficult to establish. Vaccination during the incubation period of existing infection, stress-induced disease precipitation, or coincidental timing with unrelated disease emergence may account for apparent vaccination-associated illness. Animals developing respiratory signs following vaccination should receive appropriate diagnostic evaluation and treatment rather than assuming vaccine causation.

Vaccination is contraindicated in animals with known hypersensitivity to vaccine components or animals that have experienced previous allergic reactions to Pasteurella/Mannheimia vaccines. Severe previous reactions including anaphylaxis represent absolute contraindications to revaccination with the same product. In essential situations where vaccination of hypersensitive animals is considered necessary, veterinary supervision with emergency treatment capability and possible premedication with antihistamines may reduce reaction risk.

Clinically ill animals should not be vaccinated until they have recovered and regained health status adequate to mount effective immune responses. Animals with active respiratory infections, systemic diseases, severe parasitism, or significant nutritional deficiency may fail to develop protective immunity and face increased adverse reaction risk. Deferring vaccination until health is restored ensures better outcomes for individual animals and overall program success.

Animals receiving immunosuppressive therapy, particularly corticosteroids, should not be vaccinated until treatment is completed and immune function has recovered. A minimum two-week interval between discontinuation of immunosuppressive medications and vaccination allows immune system recovery necessary for effective response. Animals requiring ongoing immunosuppressive therapy for chronic conditions present challenging vaccination decisions requiring veterinary guidance.

Vaccination of animals in advanced pregnancy warrants careful consideration due to potential stress impacts and theoretical risks of immune stimulation during late gestation. While most Pasteurella/Mannheimia vaccines are not specifically contraindicated in pregnant animals, many producers prefer to vaccinate breeding stock before breeding or during early pregnancy rather than in the final trimester. Animals vaccinated during late pregnancy should be monitored for any signs of pregnancy complications.

Concurrent administration of multiple vaccines during single handling events is common practice in sheep and goat management and is generally considered safe when vaccines are administered at separate anatomical sites. Pasteurella/Mannheimia vaccines may be given alongside clostridial vaccines, footrot vaccines, and other routine immunizations without significant interaction concerns. However, combining multiple vaccines at identical injection locations should be avoided to allow differentiation of site reactions and prevent potential adjuvant interactions.

Antibiotic therapy does not directly interfere with killed bacterial vaccine responses, as the vaccine contains no live organisms susceptible to antimicrobial activity. However, animals requiring antibiotic treatment for active infections may have compromised immune function that reduces their response to vaccination. When practical, completing antibiotic therapy and allowing recovery before vaccination optimizes immune response development.

Non-steroidal anti-inflammatory drugs administered for pain or fever management do not significantly impair vaccine responses and may be used if indicated for patient comfort. However, corticosteroids have immunosuppressive effects that may substantially reduce antibody production following vaccination. Avoiding corticosteroid administration around the time of vaccination preserves immune response quality. If corticosteroid therapy is essential, rescheduling vaccination to allow adequate washout periods is preferred.

Parasiticide administration does not interact directly with respiratory vaccines and may proceed according to routine schedules. Heavy parasite burdens may compromise immune function and reduce vaccine efficacy, making strategic deworming before vaccination beneficial in parasitized animals. Ensuring good nutritional status and controlling concurrent health challenges supports optimal immune response to vaccination across all product types.

Handler safety during vaccine administration requires attention to injection technique and accidental exposure prevention. Self-injection of adjuvanted vaccines can cause persistent inflammatory reactions and granulomatous lesions requiring medical attention. Personnel administering vaccines should use appropriate needle safety devices, avoid needle recapping after use, and maintain careful attention during injection procedures. Any accidental human injection should prompt immediate medical consultation.

Vaccination does not provide complete protection against respiratory disease, and vaccinated animals may still develop pneumonia when exposure pressure is severe or when other predisposing factors overwhelm immune defenses. Vaccination should be integrated with management practices that reduce stress, ensure adequate nutrition, provide appropriate housing and ventilation, and minimize disease exposure from high-risk sources. Producers relying solely on vaccination without addressing environmental and management risk factors may experience disappointing results.

Timing of vaccination relative to stress events significantly influences protection levels achieved. Vaccine administration during active stress periods results in reduced immune responses compared to vaccination during normal, low-stress conditions. Ideally, vaccination should occur three to four weeks before anticipated stress events to allow immune response development while animals remain unstressed. Emergency vaccination during disease outbreaks provides limited immediate benefit but helps protect animals not yet infected.

Proper vaccine storage maintains product potency and ensures efficacy at administration. Products should be stored under refrigeration at labeled temperatures, protected from freezing and light exposure, and used before expiration dates. Temperature excursions during storage or transport to the field may compromise vaccine integrity without visible changes to product appearance. Using temperature monitoring devices and maintaining proper cold chain practices from purchase through administration protects product investment.

Documentation of vaccination programs supports disease management evaluation, regulatory compliance, and adverse event investigation. Records should include product identification, lot numbers, administration dates, animal identification, injection sites, and any adverse reactions observed. Complete records prove valuable when evaluating program effectiveness, investigating disease occurrences in vaccinated animals, or reporting adverse events to manufacturers.

Pasteurella/Mannheimia vaccines require refrigerated storage at temperatures between 2°C and 8°C (35°F to 46°F) from manufacture through administration to maintain biological activity. Temperature excursions above or below this range may inactivate vaccine antigens or damage adjuvant systems, rendering products ineffective while appearing normal upon inspection. Dedicated vaccine refrigerators with temperature monitoring and alarm systems provide optimal storage conditions for valuable biological products.

Field handling during vaccination sessions should maintain cold chain integrity as much as practical under working conditions. Vaccines should be transported to working areas in insulated coolers with ice packs and returned to refrigeration during extended breaks between animal groups. Direct sunlight exposure should be avoided, as ultraviolet light can damage biological products even when temperature remains controlled. Multi-dose vial contents should be withdrawn only with sterile needles, and opened vials should be used within labeling guidelines, typically within 24 hours.

Disposal of unused vaccine, expired products, and used administration equipment should follow applicable regulations for biological and medical waste. Many jurisdictions have specific requirements for veterinary biological disposal that differ from standard waste handling. Used needles and syringes require placement in puncture-resistant sharps containers for safe disposal. Establishing proper disposal procedures and maintaining compliance records protects human health and demonstrates responsible product stewardship.

Sheep breeds demonstrate generally similar responses to Pasteurella/Mannheimia vaccination, though management system differences among breeds may influence program design and timing. Fine wool breeds managed in extensive range systems may face different respiratory disease challenges than meat breeds in intensive feedlot situations. Tailoring vaccination timing to specific production calendar events such as shearing, weaning, or shipping ensures protection during breed-specific high-risk periods.

Hair sheep breeds including Katahdin, St. Croix, and Barbados Blackbelly respond appropriately to respiratory vaccination and benefit from disease prevention programs in endemic situations. While some hair sheep breeds are promoted as having enhanced disease resistance compared to wool breeds, this does not eliminate the need for vaccination when respiratory disease pressure exists. Management decisions should be based on operation-specific disease history rather than general breed reputation assumptions.

Goat breed responses to Pasteurella/Mannheimia vaccination appear consistent across dairy, meat, and fiber types, though product selection requires attention due to limited vaccine labeling specifically for caprine species. Many products labeled for cattle or sheep are used extra-label in goats based on veterinary judgment. Dairy goat operations may need particular attention to milk withdrawal considerations if applicable for selected products, while meat goat operations focus on meat withdrawal compliance around marketing periods.

Young animal vaccination timing requires balancing protection needs against potential maternal antibody interference with vaccine response. Lambs and kids from vaccinated dams receive passive immunity through colostrum that provides early life protection but may interfere with active immunization if vaccination occurs while maternal antibody levels remain high. Most programs target vaccination at or near weaning when maternal immunity has waned sufficiently to permit effective active immunization.

Alternative respiratory vaccines targeting different pathogens or using different technologies may complement or substitute for Pasteurella/Mannheimia products depending on disease complex characteristics in specific populations. Vaccines against parainfluenza virus, respiratory syncytial virus, and other viral agents address viral components of the respiratory disease complex that bacterial vaccines do not cover. Combination products containing multiple respiratory antigens provide broader spectrum protection with single-product convenience.

Antibiotic therapy using products effective against Mannheimia haemolytica provides therapeutic intervention when vaccination has not prevented disease or when unvaccinated animals develop pneumonia. Oxytetracycline, tilmicosin, florfenicol, and tulathromycin represent commonly used antimicrobials for treating pneumonic pasteurellosis in sheep and goats. Selection should consider bacterial sensitivity patterns, withdrawal time requirements, and species-specific safety considerations, with veterinary guidance informing treatment decisions.

Anti-inflammatory medications including flunixin meglumine and meloxicam provide supportive therapy for animals with respiratory disease by reducing fever, inflammation, and associated discomfort. These products do not replace antimicrobial therapy but complement antibiotic treatment by addressing inflammatory components of disease pathophysiology. Use in food-producing animals requires attention to species-specific approvals and withdrawal time compliance.